Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.49 |
| ▸ | CDK2 | P24941 | 9/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953217 | 0.89 | CDK2 (0.62) | GSK3BCDK2CCNE1 | |
| SCHEMBL13304953 | 0.88 | GSK3B (0.49) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13304826 | 0.84 | GSK3B (0.52) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13305601 | 0.83 | CDK2 (0.54) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13304888 | 0.79 | CDK2 (0.54) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13305093 | 0.78 | TRPC3 (0.41) | GSK3BCDK2NPC1RAB9AKDM4E | |
| SCHEMBL13146184 | 0.77 | GSK3B (0.50) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13146048 | 0.77 | GSK3B (0.77) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305042 | 0.77 | HRH4 (0.50) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953175 | 0.77 | CDK2 (0.62) | GSK3BCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |